US Patent

US12514819 — Colchicine drug-to-drug interactions

Method of Use · Assigned to Rxomeg Therapeutics LLC · Expires 2036-11-22 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent describes the use of oral colchicine solutions in combination with other therapeutics while minimizing toxic interactions.

USPTO Abstract

The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.

Drugs covered by this patent

Colcrys (COLCHICINE) · Scilex Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2814`	—	Colcrys

Patent Metadata

Patent number: US12514819
Jurisdiction: US
Classification: Method of Use
Expires: 2036-11-22
Drug substance claim: No
Drug product claim: No
Assignee: Rxomeg Therapeutics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.